Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics

被引：0
|
作者：
Karagianis, JL [1 ]
Dunayevich, E
机构：
[1] Eli Lilly Canada Inc, Scarborough, ON, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2005年 / 66卷 / 01期
关键词：
D O I：
10.4088/JCP.v66n0118f
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [41] Changes in the atherogenic risk factor profile according to degree of weight loss
    Reinehr, T
    Andler, W
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (05) : 419 - 422
  • [42] RISK OF FALLS AND FRACTURES ASSOCIATED WITH CONCOMITANT USE OF ACETYLCHOLINESTERASE INHIBITORS AND ATYPICAL ANTIPSYCHOTICS AMONG OLDER ADULTS WITH DEMENTIA
    Rege, S.
    Aparasu, R. R.
    Johnson, M. L.
    Chen, H.
    Carnahan, R.
    Holmes, H. M.
    [J]. VALUE IN HEALTH, 2020, 23 : S206 - S206
  • [43] Impact of hormonal profile on cardiovasular risk factors among patients treated with atypical antipsychotics
    Vallieres, M
    Després, JP
    Bouchard, RH
    Tchernof, A
    Demers, MF
    Villeneuve, J
    Roy, MA
    Alméras, N
    [J]. OBESITY RESEARCH, 2005, 13 : A123 - A123
  • [44] Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara
    Giacomo Chiabrando
    Stefano Bianchi
    Elisabetta Poluzzi
    Nicola Montanaro
    Paola Scanavacca
    [J]. European Journal of Clinical Pharmacology, 2010, 66 : 661 - 669
  • [45] Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara
    Chiabrando, Giacomo
    Bianchi, Stefano
    Poluzzi, Elisabetta
    Montanaro, Nicola
    Scanavacca, Paola
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (07) : 661 - 669
  • [46] Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
    Riordan, Henry J.
    Antonini, Paola
    Murphy, Michael F.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2011, 4 (05): : 292 - 301
  • [47] VISTA: A NOVEL PSYCHOSOCIAL TREATMENT TO IMPROVE METABOLIC RISK FACTORS FOR PATIENTS ON ATYPICAL ANTIPSYCHOTICS
    Velligan, Dawn I.
    Medellin, E. M.
    Castillo, D. A.
    Moore, T. A.
    Li, X.
    Miller, A. L.
    [J]. SCHIZOPHRENIA BULLETIN, 2011, 37 : 284 - 284
  • [48] Medication use patterns and costs associated with atypical antipsychotics in the treatment of bipolar disorder
    Zhu, B.
    Kulkarni, P. M.
    Stensland, M. D.
    Ascher-Svanum, H.
    [J]. BIPOLAR DISORDERS, 2007, 9 : 114 - 114
  • [49] Mortality Risk with Use of Atypical Antipsychotics in Late-life Bipolar Disorder
    Bhalerao, Sachin
    Chang, Claire
    Kales, Helen C.
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2011, 19 (03): : S95 - S95
  • [50] Cardiovascular risk with concomitant use of stimulants and atypical antipsychotics in US children and adolescents
    Zhang, Chengchen
    Spence, O'Mareen
    Reeves, Gloria
    dosReis, Susan
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 589 - 589
12345